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1. Introduction 
Recent clinical trials have shown therapeutic vaccines to be promising treatment modalities 
for prostate cancer. Additional strategies are being investigated that combine vaccines and 
standard therapeutics as anti-hormone treatment to optimize the vaccines’ effects. 
Previous studies with Gonadotropin Releasing Hormone (GnRH/LHRH) vaccines have 
demonstrated the usefulness of immunization against this hormone in prostate cancer. To this 
purpose, we generated the completely synthetic GnRHm1-TT peptide which has been 
validated in a proof of concept formulated together with Montanide ISA 51 adjuvant. Such 
vaccine preparation induced a significant anti-GnRH immune response and correspondingly 
reduced testosterone to castration levels and thus produce a biological response in hormone-
dependent tumors. As a novel strategy the GnRHm1-TT peptide has been also emulsified with 
the adjuvant combination Montanide ISA 51 and VSSP. The use of this candidate in healthy 
animal models showed a significant increase in the anti GnRH immune response in 
comparison with the previous candidates, including their advantages regarding prostate and 
its testicle atrophy. Moreover, the use of the GnRHm1-TT/Montanide ISA 51/VSSP vaccine 
candidate produced a significant inhibition of tumor growth in mice transplanted with 
hormone-sensitive murine tumor Shionogi SC-115. The development of a Phase I clinical trial 
in patients with advanced prostate cancer using GnRHm1-TT/Montanide/VSSP vaccine, 
demonstrated the safety of using this candidate in humans as well as the therapeutic elements 
which must be demonstrated more widely in future clinical trials. 
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2. Epidemiology of prostate cancer 
Prostate cancer is the most commonly diagnosed malignancy in men in the Western 
Hemisphere, with 33% incidence rate and the second leading cause of cancer death in men, 
exceeded only by lung cancer despite the efforts to achieve early diagnosis of disease through 
the use of the serological marker "prostate specific antigen” (PSA). Worldwide, there are about 
650 000 reported new cases of prostate cancer each year and a mortality of about 200 000 cases. 
Autopsy studies in men show that 70% of men develop prostate cancer sometime in their lives, 
although many of them are clinically irrelevant (Russel et al, 1994; Cancer Statistics, 2008). 
Prostate cancer is diagnosed in a clinically relevant stage in one out of six men around the 
world and is usually diagnosed by elevated levels of prostate specific antigen (PSA) or the 
presence of an abnormal digital rectal examination.  
The Prostate Specific Antigen (PSA), is a protein produced by normal and pathological 
prostate cells. This protein is found in relatively small levels in the bloodstream of men with 
normal prostate, however, is considerably increased in most individuals suffering from a 
malignant disease of the prostate, but also tends to increase in benign diseases of the gland 
such as prostatitis and benign prostatic hyperplasia (BPH).  
While assessing the levels of PSA takes into account the individual's age, it is generally 
considered that these values may reach up to 4 ng/mL (Sonpavde et al, 2010). 
Unfortunately, however, the PSA does not distinguish between the stages of the disease.  
3. Prostatic tumurogenesis 
Prostate cancer seems to develop over a period ranging from 20 to 30 years (Kabalin et al, 
1989; Sacker et al, 1996). In most cases, the tumurogenesis begins as a prostatic inflammatory 
atrophy which progresses to prostatic intraepithelial neoplasia (PIN), which in some cases 
leads to carcinoma (De Marzo et al 2003, Nelson et al, 2007). In addition to genetic changes 
occurred, androgens act as promoters of proliferation and prostate growth. Thus, 
testosterone passes into the prostate cell where the action of the enzyme 5 alpha reductase is 
converted to its metabolically active form, dihydrotestosterone (DHT). Once DHT binds to 
the receptor in the cytoplasm, this favors the formation of dimers crossing the nuclear 
membrane where the complex binds to genes with androgen-responsive elements, a process 
modulated by co-activators and co-repressors (You and Tindall, 2004). 
Thus, if normal prostatic epithelial cells are deprived of testosterone, this progresses to 
death by apoptosis. Similarly, the majority of prostatic adenocarcinomas are androgen-
dependent, which means they are responders to testosterone hormone ablation. This 
behavior of prostate cells has influenced therapeutic concepts in prostate cancer for decades 
(Culig et al, 2005). Thus even in cases of metastatic disease, the first therapeutic step is 
represented by androgen suppression, which causes death by apoptosis in most prostate 
cells and leads to remission in about 85% to 90% of individuals. 
4. Current therapies in prostate cancer 
Prostate cancer patients at initial stages of the disease are treated successfully with radical 
prostatectomy or radiation therapy, however, approximately 30–40% of them will ultimately 
develop recurrent diseases (Roehl et al, 2004).  
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Once prostate cancer reach the prostatic capsule and seminal glands, the androgenic 
ablation represents the most useful therapeutic procedure since the decade of the 40´s of the 
last century (Culig et al, 2005; Pienta et al, 2006). The normal intervention of the prostate 
cancer includes: the surgical castration, the use of estrogens, anti-androgenic therapy to 
inhibit the testosterone actions and, the use of GnRH analogues which prevent the 
production of androgens in the testicles. 
The anti-hormones therapies, although very much in use, have various inconveniences. 
Thus, the surgical castration is not ethically accepted by most patients. The estrogens, such 
as the diethyl-stilbestrol (DES) are highly toxic to the cardiovascular system and the anti-
androgens frequently produce severe gastro-intestinal toxicity (Finstad et al, 2004) while 
pituitary adenomas and hot flush during the first weeks of treatment are reported for GnRH 
analogs treatment. However, the most important drawback of anti-hormonal therapy in 
prostate cancer consists in that the benefit of this therapy last for an average of between 18 
and 36 months (Casper et al, 1991). At that stage those clones of cells that escaped to the 
requirements of the absence of testosterone or lower levels, begin to grow or proliferate as 
castration resistant prostate cancer (CRPC) and emerge as the predominant cell phenotype. 
When CRPC appears, chemotherapy and steroids represent the alternative palliative 
treatment left for patients who no longer respond to hormone therapy. The half-life for these 
patients ranges between 18 and 24 months (Tannock et al, 2004). Of the many treatment 
approaches for recurrent prostate cancer that no longer responds to hormonal agents, 
immunotherapy is particularly promising, due to several unique characteristics of both the 
disease and the treatment. 
5. Prostate cancer immunotherapy 
Prostate cancer is a relatively indolent disease, allowing time for the immune system to 
generate an immunologic response. Furthermore, since the prostate is a nonessential organ, 
targeting prostate cancer-associated antigens are unlikely to have significant negative side 
effects. Finally, therapeutic cancer vaccines have been shown to be much less toxic than 
chemotherapy, hormonal therapy or targeted therapies, thus significantly improving a 
patient's quality of life. 
Studies in animals and humans developed over decades using non-specific immune 
therapies, suggest the usefulness of these therapies in prostate cancer. However, these 
therapies have been used mainly in advanced stages of cancer. Immunotherapies are 
classified as passive and active. The former include the treatment with immunomodulatory 
substances, the infusion of cytokines and immune effector agents such as antibodies or 
lymphocytes. 
In medical practice the most widely used cytokine-stimulating factor has been the 
Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF). This cytokine is known to 
act at different levels of the immune response which includes the stimulation to arachidonic 
acid release in neutrophils and active cellular response mediated by antibodies (Weisbart et 
al, 1985).  
An active immunotherapy vaccine includes strategies in which the goal is to produce an 
immune response against the tumor/host factors that aid the maintenance and growth of 
metastatic tumor (Rini et al, 2004).  
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Ideally, therapeutic prostate cancer vaccines should induce a focused antitumor immune 
response by targeting defined tumor-associated antigens (TAAs) through TH1 cell 
stimulation. The ideal TAA should be specific to, or overexpressed on the surface of prostate 
cancer cells. Several prostate-associated TAAs have been identified and that include: the 
prostate specific antigen (PSA), a 34-kD kallikrein-like serine protease expressed almost 
exclusively by prostate epithelial cells and is the most widely used serum marker for 
diagnosis and monitoring of prostate cancer (Freedland et al, 2008; Madan et al, 2009). The 
prostate specific membrane antigen or PSMA which is a 100-kD transmembrane 
glycoprotein commonly found on the surface of late stages, undifferentiated metastatic 
prostate cancer and is an imaging biomarker for staging and monitoring of therapy. It also 
represents an attractive antigen for antibody-based diagnostic and therapeutic intervention 
in prostate cancer, since it is highly restricted to the prostate and overexpressed in all tumor 
stages (Fishman et al, 2009). The prostatic acid phosphatase or PAP is a secreted 
glycoprotein (50 kDa) that serve as a well-known tumor marker of differentiated prostate 
epithelial cells (Becker et al, 2010) whose primary biologic function is still unclear. Another 
potential target, TARP, is a protein expressed in patients with prostate and breast cancer 
and is present in both normal and malignant prostate cancer tissue. It is found in about 95% 
of prostate cancer specimens, making TARP a promising target antigen for cancer vaccines 
(Maeda et al 2004; Epel et al, 2008). Recently, a prostate-specific gene encoding a protein 
named NGEP has been discovered. The full length protein (NGEP-L) is expressed in normal, 
hyperplastic and cancer prostate tissue (Cereda et al, 2010).  
Despite the long list of tumor markers, PSA has been the most useful TAA as a diagnostic 
tool and for immunotherapy. In this sense, PSA has been used as part of the PSA-TRICOM 
vaccine design, which showed a beneficial impact on metastatic CRPC patients and is 
currently in Phase III clinical trial (Bavarian Nordic, 2011).  
As part of the immune response modulation, Cytotoxic Lymphocite Antigen 4 (CTLA-4), 
represents an important immune checkpoint molecule expressed after activation by an APC. 
CTLA-4 blocking could disrupt the transmission of the regulatory signal and may increase 
the immune response of CTLs against tumor cells (Fong et al, 2008). In this sense, 
Ipilimumab is a fully humanized monoclonal antibody against CTLA-4 that demonstrated 
PSA decline in a Phase I clinical trial (Small et al, 2007) and is currently in Phase III trial. 
(http://www.clinicaltrials.gov).  
The most successful prostate cancer immunotherapy intervention is represented however, 
by the ex vivo vaccine called "Provenge" or "Sipuleucel T", which is generated from each 
patient’s own Peripheral Mononuclear Blood Cells (PMBCs), that are later “charged” with 
the fusion protein PAP/GM-CSF and the GM-CSF. (Burch et al, 2000). These 
immunotherapy demonstrated a significant improvement in the overall survival for 
Sipuleucel-T (25.8 months) vs. placebo (21.7 months) (Kantoff et al, 2010) and has been 
registered by the FDA in the United States and is the only therapeutic vaccine of its kind in 
the world for this condition.  
Combining therapeutic cancer vaccines with hormonal therapies is a potential approach for 
hormone-sensitive tumors, such as breast and prostate cancer. Preclinical data indicate that 
testosterone suppression affects not only prostate tumors, but also the immune system 
(Aragon et al, 2007). Increasingly data suggest that androgen deprivation therapy (ADT) in 
prostate cancer can augment the immune response by increasing T-cell infiltration into the 
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prostate (Mercader et al, 2001). Furthermore, ADT has been shown to decrease immune 
tolerance of TAAs, increase the size of the thymus (where CTLs are produced), and enhance 
the T-cell repertoire (Drake et al, 2005; Sutherland et al, 2005; Aragon et al, 2007; Goldeberg 
et al, 2007). It may also stimulate CTLs by reducing the number of regulatory Tcells (Tregs), 
improving immune-mediated tumor-specific response (Wang et al, 2009). 
6. Vaccines design with autologous molecules 
Immunization against endogenous molecules requires a sufficient level of neutralizing 
antibodies during the treatment period to obtain the desired effect. To produce an immune 
response against these molecules, several of which are not immunogenic thenselves, many 
strategies, such as the coupling to a carrier protein and the use of powerful adjuvants are 
required (McKee et al, 2010).  
6.1 Prostate cancer immunotherapy based on GnRH. State of the art 
GnRH-based vaccines represent a promising anti-hormonal treatment alternative in prostate 
cancer, because these can reduce serum testosterone to castration levels, avoid the "hot 
flushes” produced by GnRH analogues and can be administered in acute and complicated 
forms of prostate cancer. In turn, the ability to generate a memory immune response in 
vaccinated patients allows them to do without medications for relatively long periods of 
time which also results in lower medication costs and marketing. This aspect gives vaccines 
high added-value and very competitiveness in the market.  
6.1.1 Carriers molecules to GnRH vaccine delivery 
The most often used approach to make a peptide immunogenic, is to couple it to a protein 
molecule. Commonly used carrier proteins are KLH, TT, DT, OVA, BSA and HSA. The 
origin of the carrier protein could be of importance for the level of immunogenicity of the 
conjugate. The use of “foreign” proteins is expected to result in conjugates with a stronger 
immune response. In general, most exogenous proteins can be used as carriers, although 
non-mammalian proteins are expected to be more immunogenic. Additionally, the site of 
conjugation may determine the efficacy of the immunization. Conjugation via glutamine at 
position 1 induced a higher GnRH specific antibody response and reduced testosterone 
levels in rabbits more effectively than conjugation via positions 6 or 10. Similarly, no 
difference in GnRH antibody response has been observed in male sheep when GnRH was 
conjugated to KLH via a substituted cysteine either at position 1, 6 or 10 (Goubau et al, 
1989). These results have been confirmed in mice. At the same time, specificity of the 
antisera depend on the site of conjugation. So, experiment carried out by conjugation via 
cysteine on position 1 resulted in C-terminal directed antibodies, conjugation via cysteine on 
position 10 generated N-terminal directed antibodies, while conjugation via cysteine at 
position 6 generated both N- and C-terminal antibodies (Silversides et al, 1988). In contrast, 
Ferro et al. (1998) showed that the N-terminal conjugation via a cysteine substitution at 
position 1 resulted in effective immunization of rats, while conjugation via cysteine 
substitution at position 10 was not effective. Other groups used native GnRH extended with 
glycine and cysteine, conjugated to a carrier protein (Ferro et al., 1996; Miller et al., 2000) or 
longer spacer peptides (Simms et al., 2000; Parkinson et al., 2004). Thus, it seems that 
immunization with GnRH peptides, conjugated to a carrier protein via the N-terminus 
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results in more effective antibody titers than conjugation via the C-terminus. However, this 
was not confirmed in all studies and may depend on the chemical approach used and 
substitution of amino acids required for coupling. 
One of the most promising vaccine candidate based on GnRH have been developed by 
United Biomedical (UBI, Hauppauge, USA), which is a complete synthetic vaccine 
comprising the GnRH decapeptide, several promiscuous T-cell epitopes and a domain from 
Yersinia invasin protein to improve the immunogenicity of the GnRH-T cell epitope 
constructs (Finstad et al., 2004). Although the single constructs were not completely effective 
in rats, mixtures of constructs caused serum testosterone to drop to very low levels, whereas 
testes weights were less than 25% of the controls. The antigens in a water-in-oil formulation 
and oil-in-water formulation were effective in baboons and dogs, respectively. Phase I 
clinical trials have been planned recently using this vaccine candidate, however, no results 
have been published so far.  
In the hope of developing a better anti GnRH vaccine apart from the mentioned carrier 
molecules, some alternatives have been used like the Mycobacterium tuberculosis hsp 70, 
linked to GnRH-6-DLys by elves and Roitt’s group employing either Ribi adjuvant or 
incomplete Freund’s adjuvant. With either adjuvant, all mice produced sufficient antibodies 
to cause atrophy of the uro-genital complex. LHRH-6-DLys was also employed after 
conjugation to albumin and mixed with Specol as adjuvant. These vaccine candidate have 
been used in pigs as an alternative to castration (Zeng et al, 2002).  
Previous studies of the Population Council group (Ladd et al,1990) found that the 
conjugation of TT at the N-terminal was better than at the C-terminal. Desirability of 
keeping the LHRH C-terminal free has also been advocated by Ferro et al. (2002). Linkage of 
TT at the N-terminal in Des 1-GnRH, where glutamic acid at position 1 is replaced by 
cysteine, gives better conjugate that induces antibodies specific to the classical GnRH-1. 
Dimerization enhances antibody titers but the monomer conjugate was found to be more 
effective (Ferro et al., 2002). 
6.1.2 Recombinant vaccines against LHRH/GnRH 
Enough data have accumulated to conclude that the vaccines against GnRH-I can be 
employed in humans and in animals without side-effects. These vaccines are beneficial in 
the treatment of prostate carcinoma patients to reduce fertility of wild animals and sex 
steroid hormone production thus regulating estrus and libido of animals raised for meat 
production.  
Recombinant vaccines would be substantially cheaper to produce at industrial scale than 
synthetic vaccines conjugating multiple copies of GnRH with receptor-binding domain of 
Pseudomonas exotoxin (Hsu et al, 2000). This recombinant protein containing 12 repeats of 
LHRH along with this carrier generated high antibody titres in rabbit and is recommended 
for the treatment of hormone-sensitive cancer. At the same time, genes for three repeats of 
GnRH linked through an eight amino acid hinge fragment of human IgG1 to a helper T-cells 
peptide of measles virus have been constructed in order to increase immunogenicity. The 
DNA coding for a dimer of this complex assembly was fused to the C-terminal (199–326)-
encoding sequence of asparaginase (Jinshu et al.(2006). This protein was expressed in E. coli 
and generated an anti LHRH response .  
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Talwar et al. (2004) reported the ability of a multimer recombinant anti-LHRH vaccine to 
cause decline of testosterone to castration level and atrophy of rats prostate. In the design of 
this vaccine, DT/TT used as carriers in the previous semisynthetic vaccines were replaced 
by four or five T non-B-cell peptides interspersed in four or five LHRH units. This was done 
to avoid carrier-induced epitope suppression brought by DT/TT carrier conjugates (Sad et 
al., 1991), and also to communicate through an array of these T-cell determinants with MHC 
across the spectrum in a polygenetic population. The genes were assembled, cloned and 
expressed at high level (15% of total cellular protein) in E. coli (Gupta et al., 2004). Employing 
a buffer at pH 3, it was possible to extract the protein from inclusion bodies employing low 
concentrations of chaotropic reagents (2 mol/l urea instead of 8 mol/L). The protein was 
purified and refolded to native immunoconformation (Raina et al., 2004).  
The company Biostar, (Saskatoon, Canada), developed a GnRH vaccine comprising a 
recombinant fusion protein produced in E. Coli bacteria. Several copies of a GnRH-tandem 
molecule were fused to the terminal ends of leukotoxin. This vaccine has shown full efficacy in 
young pigs and cats (Manns and Robbins, 1997; Robbins et al., 2004), while antibody responses 
were variable in heifers (Cook et al., 2001). For application in prostate cancer patients, the 
vaccine called NorelinTM, was out-licensed to York Medical BioSciences (Mississauga, Canada). 
In 2001 clinical studies indicated that the vaccine with an aluminium salt-based adjuvant was 
safe to be used in humans, however it was not immunogenic enough to raise a sufficiently 
strong immune response. In 2003, a second clinical trial  was initiated. This vaccine was well 
tolerated with ´no major adverse events (www.ymbiosciences.com). In a recent press release it 
has been announced a trial in prostate cancer patients in China (www.unitedbiomedical.com). 
On the other hand Proterics developed a GnRH vaccine containing the GnRH decapeptide 
with an additional glycine and cysteine ´Prolog´, which was out-licensed to ML Laboratories. 
They completed phase II clinical studies in 2000, but at present no results have been published 
(www.mllabs.co.uk). Most recently, the chimeric peptide called GnRH3–hinge–MVP which 
contains three linear repeats of GnRH (GnRH3), a fragment of the human IgG1 hinge region, 
and a T-cell epitope of measles virus protein (MVP). The expression plasmid contained the 
GnRH3–hinge–MVP construct ligated to its fusion partner (AnsB-C) via a unique acid labile 
Asp–Pro linker. The recombinant fusion protein was expressed in an inclusion body in 
Escherichia coli under IPTG or lactose induction and the target peptide was easily purified 
using washing with urea and ethanol precipitation. The target chimeric peptide was isolated 
from the fusion partner following acid hydrolysis and purifed using DEAE–Sephacel 
chromatography. Further, immunization of female mice with the recombinant chimeric 
peptide resulted in generation of high-titer antibodies specifc for GnRH. The results showed 
that GnRH3–hinge–MVP could be considered as a candidate anti-GnRH vaccine, however the 
reports just include their use as immunocastration vaccine (Jinshu X, 2006). In 2008, the group 
of Li Yu and colleagues at Department of Biochemistry, Medical College, Jinan University in 
China developed GnRH-PE40, one of the recombinant single-chain fusion proteins consisting 
of GnRH fused to a binding defective form of pseudomonas aeruginosa exotoxin A (PE40), which 
has been developed as a preparation with potential functions of immune castration in male 
reproductive system (Li et al, 2008). 
6.1.3 Adjuvants and other strategies employed for enhancement of immune response 
The adjuvants most commonly used in human and veterinary vaccines are oil-based 
adjuvants and aluminum hydroxide (Alum). Responses to Alum are often low and of short 
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duration. Oil-based adjuvants are effective in generating a high immune response, but may 
cause inflammatory reactions. Complete Freunds adjuvant (CFA) is a mineral oil, which 
forms a water-in-oil emulsion, and contains killed and dried bacteria to stimulate the 
immune response. This combination induces high antibody responses; because of these 
characteristics and CFA being one of the oldest adjuvants used, it is ´the gold standard´ 
among adjuvants. However, due to the inflammatory side effects, which may occur at the 
site of injection, its use is limited to experimentation in laboratory animals.  
Instead of whole bacteria, bacterial compounds such as muramyl dipeptide (MDP), 
lipopolysaccharide (LPS) or monophosphoryl lipid A (MPL) can be used to stimulate the 
immune system. Alternative immune stimulating compounds are saponins, i.e. Quil A and 
the purified QS21 fraction, bacterial DNA, microparticles, Iscoms, liposomes, virus-like 
particles, block polymers and dimethyldioctadecylammonium bromide(DDA). 
Among the new adjuvant in development we count Titermax, which contains non-mineral 
oil and a block polymer that forms a water-in-oil emulsion, and RIBI adjuvant, which 
contains non-mineral oil with microbial components that forms an oil-in-water emulsion 
(Bennett et al., 1992; Kiyma et al, 2000). The comparison of CFA to Montanide ISA 51, which 
forms a water-in-mineral oil emulsion, showed that CFA was superior to ISA 51 with 
respect to antibody titers and subsequent effects on testosterone levels when tested in sheep. 
In contrast, others found effective GnRH antibody responses using ISA 51 combined with 
DDA in baboons (Finstad et al., 2004). In conclusion, effective antibody titers can be 
generated with adjuvants other than CFA, however, responses may differ among studies 
due to differences in target species, number of immunizations, antigen type and dose. 
A novel retro-inverso GnRH composed of D-amino acids assembled in reverse order (C to N 
terminus) was found to induce high titers of antibodies reactive with native GnRH without 
conjugation to a carrier or use as an adjuvant (Fromme et al., 2003). On the other hand non-
ionic surfactant vesicles, aluminium hydroxide, Quil A, polylactide co glycolide acid 
(PLGA) and Quil A/PLGA combination, with their cysteine-modified LHRH linked to TT 
have been the best adjuvant used by Ferro et al. (2004) and interestingly, there exist reports 
from 1998 that the encapsulation of GnRH-6-DLys-TT in PLGA microspheres induces a bio-
effective antibody response within 15 days after a single administration, obliterating the 
necessity of repeated injections (Diwan et al, 1998)  
7. Clinical trials in prostate carcinoma patients 
Several GnRH vaccines have been developed for the treatment of prostate cancer. Clinical 
trials in patients with advanced prostate cancer revealed that in contrast to rodents and 
monkeys, high antibody titers were obtained in some, but not all treated patients. A 
reduction in prostatic size was observed in 3 out of 6 patients treated with 400 μg conjugate 
in Alum and in 1 out of 6 patients treated with 200 μg conjugate (Talwar et al., 1995). The 
same group used a vaccine comprising a modified GnRH decapeptide with a D-Lysine at 
position 6 linked to DT in the development of a Phase I/ II clinical trials in 28 patients of 
advanced stage carcinoma of prostate (12 patients at the All India Institute of Medical 
Sciences, New Delhi, India, 12 at the Post Graduate Institute of Medical Education and 
Research, Chandigarh, India, and 4 at the Urologizche Klinikum, Salzburg, Austria). The 
vaccine employed alhydrogel, an adjuvant permissible for human use. It was used at 200 µg 
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and 400 µg dose, and three injections were given at monthly intervals. The vaccine was well 
tolerated by all patients with no side-effects attributable to immunization. A 400 µg dose 
produced antibody titres >200 pg dose. Patients generating >200 pg of antibodies/ml 
benefited clinically and testosterone declined to castration levels. The prostate-specific 
antigen (PSA) and acid phosphatase declined to low levels. Ultrasonography and serial 
nephrostograms showed the regression of prostatic mass (Talwar et al., 1998). A preclinical 
study was previously developed by Fuerst in rats bearing androgen-dependent prostatic 
tumors R3327-PAP. As a result of this study carried out in Copenhagen rats implanted SC 
with the tumor fragments, after three immunizations tumor growth was suppressed 
compared to untreated controls. Surprisingly, tumor growth was also suppressed in rats 
implanted with androgen-independent Dunning tumor cells R3327-AT2.1. This 
Phenomenon is suggested to be related with the presence of a local GnRH-loop in the 
prostate, which is affected by GnRH neutralizing antibodies and produce a tumor growth 
reduction even in testosterone-independent tumors.  
A very promising approach using the GnRH antigen was developed by the Aphton 
company in USA. That comprises the GnRH molecule extended with a linker peptide of 6 
amino acids conjugated to DT. Two clinical trials with a GnRH-DT vaccine have been 
carried out at Nottingham, UK by Bishop’s group. In the first study (Simms et al., 2000), the 
vaccine was used at two doses 30 µg and 100 µg, administered three times over 6 weeks in 
12 patients with advanced prostate cancer. It was well tolerated and in five patients a 
significant reduction in serum testosterone and PSA levels was seen. Testosterone declined 
to castration level in four patients for 9 months. Since the modest results obtained in this 
trial, 3 and 15 μg doses were evaluated in order to determine how the doses reduction can 
work (Parkinson et al, 2004). As result of this approach, suppression of testosterone to 
castrate levels was detected in 2 out of 6 patients treated with 15 μg antigen, whereas none 
of the patients treated with 3 μg responded. The above-mentioned clinical studies in India, 
Austria and UK confirmed the safety of LHRH or GnRH linked to DT vaccine in prostate 
carcinoma patients. These studies further showed that in patients generating adequate 
antibodies, testosterone declined to castration levels with concomitant decline of PSA, and 
there was clinical benefit to the patients. 
8. GnRHm1-TT, a new strategy to prostate cancer immunotherapy 
The development of the vaccine candidate GnRHm1-TT has as its main invention the 
substitution of L-glycine in position 6 of the GnRH molecule by the amino acid L-proline 
and the addition of a T helper epitope of TT (Bringas et al, 2000). With this modification we 
expected to guarantee a “change” in the "U" native conformation of the natural GnRH 
peptide structure, which is known to play a pivotal role in binding to the receptor (Millar et 
al, 1977; Millar et al, 2008) and on the other hand, to generate a more rigid molecule that 
makes it more available to the immune system in the hope to break the B cells tolerance 
(Goodnow et al, 1991; Bizzini and Achour,,1995) while the incorporation of the TT 830-844 
promiscuous epitope give an additional “immunologic target” to recognize this molecule. 
(Hoskinson et al, 1990, Ferro and Stimson, 1998, Finstad et al, 2004 ). 
The high production of natural antibodies against GnRH, induced by the GnRHm1-TT 
peptide in AF and in the two types of Montanide, demonstrated the immunogenicity of the 
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peptide used and its potential to “fool” the physiological mechanisms of immunologic 
tolerance together with the fact that the Montanide ISA 51 showed some superiority over 
the FA in terms of antibody titers. 
An important fact in the development of a GnRH based vaccine has been the decision about 
the peptide doses to employ. In this sense, experiments carried out with doses ranging from 
125 to 750 µg in rats addressed the usefulness of the 750 µg doses in comparison with lower 
doses according to the time to develop the anti immune response and the anti GnRH titres. 
That demonstrate the desirability of using high peptide doses of GnRHm1-TT to achieve the 
breaking of B cell tolerance and at the same time the utility of using fortnightly and monthly 
immunization schedules. That is in correspondence with previous works using similar 
candidates (Talwar et al, 1997, Finstad et al, 2004)  
In the hope to demonstrate the feasibility of generating an effective immune response with 
the vaccine candidate GnRHm1-TT/ Montanide ISA 51 in other species of mammals, given 
that although GnRH is a hormone that is 100% homologous in all of them (Talwar et al, 
1997, Millar et al, 2008), HLA system among species produces a different behavior of the 
immune response (Friederike et al, 2008), experiments were carried out in two animal 
models that share different genetic homology; the New Zealand rabbits and Macacus 
monkeys. 
The development of an immunization schedule in both species showed that 100% of the 
animals generated anti-GnRH antibody titres, regardless of the dose used (750 µg or 1mg). 
However, the increase in dose up to 1mg, produced a significant rise in antibody titres 
generated, although this increase did not result in different levels of testosterone. 
In this sense, the results suggest that, once antibodies against GnRH hormone reach "critical" 
levels, they achieve the formation of nearly 100% of circulating immune complexes with 
GnRH and they will result in the fall of testosterone levels. That observation is in accordance 
with some reports that suggest that rather than their isotype or antibody affinity, the 
biological effect of anti-GnRH antibodies depends on the speed of its appearance and its 
maintenance in sufficient concentrations (Talwar et al 2004, Miller et al, 2006). The use of 
doses over 1 mg did not improve significantly the characteristics of the immune response 
produced, neither seemed to generate a phenomenon of immunological tolerance.  
These results have great relevance for making decisions regarding the selection of the 
peptide dose in the following of experiments in other animal models and in humans. In 
turn, the increased robustness of the Macacus irus model, allowed to explore how the 
immune response would behave when using the intramuscular route (IM). The results 
found with GnRHm1-TT formulated in Montanide ISA 51, corresponded to those obtained 
by other authors that report similar immunogenicity between IM and SC routes (Talwar et 
al, 1997). These similar behavior can be related to the ability of the adjuvant Montanide ISA 
51, similar to the AF, to produce a reservoir of antigen and its slow release to the immune 
system, which allows a better efficiency of antigen presentation by macrophages and 
Dendritic cells (DC) to T cells (Guerrero et al, 1982; Forsbucher et al, 1996). That approach 
demonstrates the feasibility of using IM route in human trials where both, the Montanide 
ISA 51 and Montanide ISA 51 VG, produce a marked local toxic effect when administered 
subcutaneously (manufacturer's data SEPPIC, France). 
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In a step forward, the vaccine candidate GnRHm1-TT/Montanide ISA 51 was evaluated in the 
Dunning R3327-H tumor model, which shares similar characteristics to cancer in humans 
(Isaacs et al, 1994). The results of the high anti-GnRH seroconversion (88%) in the model 
demonstrated the feasibility of the vaccine in generating a consistent humoral immune 
response, despite the presence of established tumor. So, despite the variability in the anti-
GnRH titres it droped testosterone levels until castration in all the animals that seroconverted 
and in consequence a significant tumor growth inhibition was observed (Table 1).  
 
Table 1. Effects of the immunization with vaccine candidate GnRHm1-TT/Montanide in 
Copenhagen rats implanted with the Dunning R3327-H tumor. 
Different letters denote significant differences calculated according to the U Mann Whitney 
test. The differences in the anti-GnRH antibody titres and Testosterone were calculated 
using a simple ANOVA and for the survival a Log Rank test was carried out. 
As an important fact it was noted that despite the uncontrolled tumor growth observed in 
cases beyond the hormone-dependence, Dunning R3327-H tumor does not generate distant 
metastases (Isaacs et al, 1978, 1986; Canena-Adams, 2007, Cho et al, 2009; Peschke et al, 
2011).  
In order to determine the direct role of the anti GnRH antibodies in the described 
immunocastration effects in healthy and tumor implanted animals, purified serum obtained 
from rabbits immunized with the GnRHm1-TT/Montanide ISA 51 vaccine candidate was 
used and tested in the mammalian COS-7 cells model (Millar et al, 2003). As a result, a gradual 
decrease in the Inositol Phosphate (IP) concentration was detected once the anti GnRH 
antibodies concentration was increased from 0,65 μg to 12.5 mg, showing the neutralizing 
capacity of the anti GnRH antibodies generated with the vaccine candidate.  
Despite the satisfactory results obtained with the use of the vaccine candidate GnRHm1-
TT/Montanide ISA 51 in the different tested models, the slow appearance of anti-GnRH 
antibodies (after 3 immunizations) and hence; the consequently slow fall in testosterone 
levels and the heterogeneity in the atrophy effects in prostate and testes in the vaccinated 
individuals, led us to a new strategy to include the use of a combination of adjuvants in 
order to enhance the immune-response attributes induced and the biological effects. 
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The use of combinations of potent adjuvants to promote the inflammatory cells to escape 
from the regulatory circuit, is an attractive idea, well addressed by the scientific literature 
that has been recently practiced in the development of preventive vaccines (Ambrosino et al, 
1992; Udono et al, 1993; Nestle et al, 1998). This strategy, however, has not been used so far 
in the development of therapeutic vaccines based on poorly immunogenic self-molecules as 
GnRH. In the current vaccine design, a Montanide ISA 51/VSSP adjuvant combination was 
explored. 
The VSSP belongs to the range of pathogen-derived adjuvants which have the ability to 
stimulate dendritic cells (DC) through receptors similar to those described in Drosophila 
Tolls (TLR). This adjuvant has within its active molecules, those classified as "dangerous", 
according to the so-called danger theory (Andersen et al, 1989, Lowell et al, 1990; Zollinger, 
1990, 1994, Jeannin et al, 2000; 2003; Matzinger et al, 2001).  
As a result of the immunization of rats with the GnRHm1-TT peptide emulsified with the 
adjuvant combination Montanide ISA 51/VSSP, a strong humoral response manifested as 
three-fold increase in anti-GnRH antibody titres and a significant improvement in the speed 
of the anti-GnRH was produced (Fig.1). 
 
Fig. 1. Graphic representation of anti GnRH seroconversion generated in male rats 
immunized with the vaccine composition GnRHm1-TT, with or without the presence of 
VSSP. Serums from different experimental groups were obtained at days 0, 30, 45, 60, and 
75. These were diluted in a blocking buffer 1:50. The T bars for each point convey the 
absorbance mean ± DE. Different letters denote statistical differences between the points 
according to the non-parametrical Kruskal Wallis analysis. 
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It also highlights the fact that this formulation, is the first to allow to obtain mean levels of 
castration at day 60 after the beginning of the immunization. In addition the adjuvant 
combination generated a reduction of over 60% of the size of the prostate and testes which 
was significantly higher than that achieved with the traditional vaccine candidate GnRHm1-
TT/Montanide and represents an unprecedented result in the development of such 
vaccines.  
The VSSP classifies as a type 2 adjuvant, acting by stimulating antigen presenting cells 
through TLR 2 and 6 by a mechanism independent of LPS, producing increased maturation 
of the humoral immune response in a Th1 pattern (personal communication) and together 
with the adjuvant Montanide ISA 51, favors the direct stimulation of the innate immune 
response (Aguiar et al, 2009). To evaluate the antitumoral potentiality of the GnRHm1-
TT/Montanide ISA 51 VG /VSSP vaccine candidate, the hormone-sensitive Shionogi SC-115 
murine prostate tumor model was used. 
Similar to the pattern described in healthy rats, immunization of DD/S mice bearing the 
Shionogi tumor generated a fast seroconversion and high antibody titers against GnRH after 
2 administrations. These results, although expected, are further evidence of the 
immunogenicity of the GnRHm1-TT peptide in a new species of rodents. In accordance with 
those anti GnRH antibodies, testosterone ablation was observed in all the immunized mice 
and a controlled tumor growth was seen in most cases (Fig. 2).  
 
Fig. 2. Tumor growth behaviour of the Shionogi tumor in DD/S mice immunized with the 
vaccine candidate GnRHm1-TT/Montanide/VSSP. The mice were immunized with the 
vaccine candidate GnRHm1-TT/Montanide/VSSP at days 0, 15, 30, 45, and 60. (n=5). The 
castrated group was orchiectomized at day 15 after the tumor cells were inoculated. The 
placebo group was immunized with the same frequency as the immunized one. The former 
group received a mixture of Montanide ISA 51 VG/VSSP. The curve comparison was made 
using the Kruskal Wallis test. Different letters denote significant differences (p<0,05). 
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Although routine prostate cancer immunotherapy refer to those interventions related to the 
use of specific TAA or cell based vaccines, and GnRH vaccines are considered just as 
hormonal ablation therapy; the introduction of powerful adjuvant as part of the GnRH 
vaccines open the possibility to works at the same time as enhancers of antigen spreading 
and DC stimulation and suppression of T regs cell population. Additionally there are 
published results (Nesslinger et al, 2007), that argue that castration alone is capable of 
inducing antibodies against tumor in both, animal models and in humans as a result of 
efficient presentation of tumor antigens obtained from apoptotic bodies.  
In the case of the vaccine candidate under study, which has the powerful components, 
Montanide ISA 51 and VSSP, we hypothesized that the apoptotic bodies resulting from 
testosterone ablation of prostate cancer cells in the presence of the “danger” signals 
produced by VSSP through TLR 2 and 6 in a context of the inflammatory enviroment, 
produce an immunological spreading of specific CTL that recognizes the most 
representative TAA. Similarly, a specific humoral response against tumor antigens can be 
reached contributing to a better antitumoral effect (Nesslinger et al, 2007). These aspects 
must be studied in depth in new preclinical and clinical studies to characterize a more 
efficient vaccine candidate GnRHm1-TT/Montanide ISA 51/VSSP as an advantageous 
alternative for the treatment of prostate cancer. In Clinical setting an important milestone of 
the trial was to demonstrate the safety of this candidate. As evidence of vaccine efficacy, 
recently the GnRHm1-TT/Montanide ISA 51/VSSP candidate (Heberprovac), have been 
employed in a Phase I clinical trial in advanced prostate cancer patients. The vaccine was 
well tolerated and no important side effects were detected. As results of immunization, all 
the 6 patients that concluded the treatment developed anti GnRH antibodies and had 
depleted the testosterone until castration levels and, in concordance normalized their PSA 
values. After 4 year of clinical and haematological follow up of the clinical trial, 5/6 patients 
are alive and keep a favourable clinical picture and normal PSA behaviour.  
9. Concluding remarks 
Therapeutic cancer vaccines have been in use for several years now. At the beginning, with 
disappointing results, but after many attempts our understanding growth in the sense of 
figuring out how the immune system works. This knowledge permitted the successful 
development of more potent vaccines and other immunotherapeutic agents that are 
currently in advanced clinical trial or registered as Sipuleucel-T.  
GnRH-based vaccines represent a promising anti-hormonal treatment alternative in prostate 
cancer, because these can reduce serum testosterone to castrate levels, avoid the "hot 
flushes” produced by GnRH analogues and can be administered in acute and complicated 
forms of prostate cancer.  
Although regularly prostate cancer immunotherapy refer to those interventions related with 
the use of specific TAA or cell based vaccines, the introduction of powerful adjuvants as 
part of the GnRH vaccines enables them to work similarly as enhancers of antigen spreading 
and DC stimulation and immune response modulation.  
The development of the vaccine candidate GnRHm1-TT have as main invention the 
substitution of L-glycine in position 6 of the GnRH molecule by the amino acid L-proline 
and the addition of a T helper epitope of TT (Bringas et al, 2000) and the use of the 
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Montanide ISA 51/VSSP adjuvant combination in order to improve the immunogenicity 
and antitumoral effects of such vaccine. Additionally, it is supposed that the vaccine 
candidate GnRHm1-TT/Montanide/VSSP take advantage of the tumor apoptosis produced 
by the testosterone ablation and the special conditions available with the use of the VSSP 
adjuvant to stimulate a successful antigen presentation to DC and a prominent 
immunological spreading of effector T cell directed to prostate TAA. Additionally as 
Nesslinger states, castration alone is capable of inducing antibodies against tumor in both, 
animal models and in humans as a result of efficient presentation of tumor antigens 
obtained from apoptotic bodies. (Nesslinger et al, 2010). 
In this context, we consider GnRH vaccine like GnRHm1-TT/Montanide/VSSP to represent 
a powerful weapon that could be employed by uro-oncologist to control the course of 
prostate cancer toward the CRPC. 
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